Skip to main content
Log in

Ziconotide

  • Adis Drug Profile
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

  • ▲ Ziconotide, an intrathecal analgesic for the management of chronic intractable pain, binds with high affinity to N-type calcium channels in neuronal tissue and obstructs neurotransmission.

  • ▲ In three pivotal, well designed trials of 5–6 or 21 days’ duration, titrated ziconotide was significantly more effective than placebo in treating chronic malignant or nonmalignant pain as assessed by mean percentage improvements from baseline in Visual Analogue Scale Pain Intensity scores.

  • ▲ Improvements in secondary endpoints (e.g. proportion of patients who responded or achieved pain relief and the change in opioid use) generally support the efficacy of ziconotide over placebo.

  • ▲ Ziconotide maintains its analgesic efficacy in preliminary results from long-term, open-label trials (data available for up to 12 months).

  • ▲ Most ziconotide-related adverse events are neurological, mild to moderate in severity, resolve over time and reverse without sequelae on drug discontinuation.

  • ▲ Low initial doses of ziconotide and gradual titration to onset of analgesia reduces the incidence and severity of adverse events.

  • ▲ No evidence of respiratory depression has been reported with intrathecal ziconotide.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Hassenbusch SJ, Garber J, Buchser E, et al. Alternative intrathecal agents for the treatment of pain. Neuromodulation 1999; 2(2): 85–91

    Article  PubMed  CAS  Google Scholar 

  2. Staats PS, Yearwood T, Charapata SG, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 2004 Jan 7; 291(1): 63–70

    Article  PubMed  CAS  Google Scholar 

  3. Bowersox SS, Luther R. Pharmacotherapeutic potential of omega-conotoxin MVIIA (SNX-111), an N-type neuronal calcium channel blocker found in the venom of Conns magus. Toxicon 1998; 36(11): 1651–8

    Article  PubMed  CAS  Google Scholar 

  4. Dougherty PM, Staats PS. Intrathecal drug therapy for chronic pain: from basic science to clinical practice. Anesthesiology 1999 Dec; 91(6): 1891–918

    Article  PubMed  CAS  Google Scholar 

  5. Gohil K, Bell JR, Ramachandran J, et al. Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium-channel antagonist, SNX-230 (ω-conopeptide MVIIC). Brain Res 1994; 653: 258–66

    Article  PubMed  CAS  Google Scholar 

  6. Wang Y-X, Bowersox SS. Analgesic properties of ziconotide, a selective blocker of N-type neuronal calcium channels. CNS Drug Rev 2000; 6(1): 1–20

    Article  CAS  Google Scholar 

  7. Mathur VS. Ziconotide: a new pharmacological class of drug for the management of pain. Semin Anes 2000; 19(2): 67–75

    CAS  Google Scholar 

  8. Gaur S, Newcomb R, Rivnay B, et al. Calcium channel antagonist peptides define several components of transmitter release in the hippocampus. Neuropharmacology 1994; 33: 1211–9

    Article  PubMed  CAS  Google Scholar 

  9. Nadasdi L, Yamashiro D, Chung D, et al. Structure-activity analysis of a Conus peptide blocker of N-type neuronal calcium channels. Biochemistry (Mosc) 1995; 34: 8076–81

    Article  CAS  Google Scholar 

  10. Villarroya M, De la Fuente M-T, Lopez MG, et al. Distinct effects of (ω-toxins and various groups of Ca2+-entry inhibitors on nicotinic acetylcholine receptor and Ca2+ channels of chromaffin cells. Eur J Pharmacol 1997; 320: 249–57

    Article  PubMed  CAS  Google Scholar 

  11. Xiao WH, Bennett J. Synthetic ω-conopeptides applied to the site of nerve injury suppress neuropathic pains in rats. J Pharmacol Exp Ther 1995; 274(2): 666–72

    PubMed  CAS  Google Scholar 

  12. Malmberg AB, Yaksh TL. Effect of continuous intrathecal infusion of ω-conopeptides, N-type calcium-channel blockers, on behavior and antinociception in the formalin and hot-plate tests in rats. Pain 1995; 60: 83–90

    Article  PubMed  CAS  Google Scholar 

  13. Wang Y-X, Gao D, Pettus M, et al. Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats. Pain 2000; 84(2–3): 271–81

    Article  PubMed  CAS  Google Scholar 

  14. Bowersox SS, Luther RR. SNX-111. Drugs Future 1994; 19: 128–30

    Google Scholar 

  15. Wermeling D, Drass M, Ellis D, et al. Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. J Clin Pharmacol 2003 Jun; 43(6): 624–36

    PubMed  CAS  Google Scholar 

  16. McGuire D, Bowersox S, Fellmann JD, et al. Sympatholysis after neuron-specific, N-type, voltage-sensitive calcium channel blockade: first demonstration of N-channel function in humans. J Cardiovasc Pharmacol 1997; 30: 400–3

    Article  PubMed  CAS  Google Scholar 

  17. European Medicines Evaluation Agency. Ziconotide: summary of product characteristics [online]. Available from URL: http://www.emea.eu.int [Accessed 2006 Jan 8]

  18. Wallace M, Ludington E, Ellis D, et al. A randomized, double-blind, placebo-controlled study of intrathecal (IT) ziconotide in adults with severe chronic pain [abstract no. 1376-P246]. 11th World Congress on Pain; 2005 Aug 21–26; Sydney

  19. Staats P, Wallace M, Presley D, et al. Long-term intrathecal ziconotide effectiveness in chronic malignant and nonmalignant pain [abstract no. 785]. J Pain 2004 Apr; 5(3 Suppl. 1): 55

    Google Scholar 

  20. Lieberburg I, Ludington E, Howard R, et al. Efficacy of intrathecal ziconotide for different pain etiologies [abstract no. 1377-P247 plus poster]. 11th World Congress on Pain; 2005 Aug 21–26; Sydney

  21. European Medicines Evaluation Agency. Ziconotide: scientific discussion [online]. Available from URL: http://www.emea.eu.int [Accessed 2006 Jan 8]

  22. Dissanayak S, Royal M, Wallace M. Incidence of adverse events in patients on long-term (at least 6 months) ziconotide [abstract no. 886]. J Pain 2003 Mar; 4(2 Suppl. 1): 73

    Google Scholar 

  23. Ellis D, Ludington E, Kartzinel R. Analysis of creatine kinase levels during intrathecal ziconotide treatment of patients with severe chronic pain [abstract no. 1378-P248]. 11th World Congress on Pain; 2005 Aug 21–26; Sydney

  24. Staats P, Charapata S, Royal M, et al. The safety profile of intrathecal ziconotide: a new non-opioid analgesic [abstract no. 839 plus poster]. 19th Annual Scientific Meeting of the American Pain Society; 2000 Nov 2–5; Atlanta

  25. Gee L, Marmon T, Narayana A, et al. Characterization of nervous system events in patients taking intrathecal (IT) ziconotide for severe chronic pain [abstract no. 1370-P240]. 11th World Congress on Pain; 2005 Aug 21–26; Sydney

  26. Charapata SG, Ellis D. Unintentional overdose with intrathecal ziconotide [abstract]. Pain Med 2002 Jun; 3(2): 190

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lyseng-Williamson, K.A., Perry, C. Ziconotide. CNS Drugs 20, 331–338 (2006). https://doi.org/10.2165/00023210-200620040-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200620040-00007

Keywords

Navigation